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Abstract
Background
Chlorproguanil-dapsone (CD) has been linked to hemolysis in symptomatic glucose-6-
phosphate dehydrogenase deficient (G6PDd) children. Few studies have explored the
effects of G6PD status on hemolysis in children treated with Intermittent Preventive Treat-
ment in infants (IPTi) antimalarial regimens. We sought to examine the joint effects of G6PD
status and IPTi antimalarial treatment on incidence of hemolysis in asymptomatic children
treated with CD, sulfadoxine-pyrimethamine (SP), and mefloquine (MQ).
Methods
A secondary analysis of data from a double-blind, placebo-controlled trial of IPTi was con-
ducted. Hemoglobin (Hb) measurements were made at IPTi doses, regular follow-up and
emergency visits. G6PD genotype was determined at 9 months looking for SNPs for the A-
genotype at coding position 202. Multivariable linear and logistic regression models were
used to examine hemolysis among children with valid G6PD genotyping results. Hemolysis
was defined as the absolute change in Hb or as any post-dose Hb <8 g/dL. These outcomes
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were assessed using either a single follow-up Hb on day 7 after an IPTi dose or Hb obtained
1 to 14 or 28 days after each IPTi dose.
Findings
Relative to placebo, CD reduced Hb by approximately 0.5 g/dL at day 7 and within 14 days
of an IPTi dose, and by 0.2 g/dL within 28 days. Adjusted declines in the CD group were
larger than in the MQ and SP groups. At day 7, homo-/hemizygous genotype was associ-
ated with higher odds of Hb <8 g/dL (adjusted odds ratio = 6.7, 95% CI 1.7 to 27.0) and
greater absolute reductions in Hb (-0.6 g/dL, 95% CI -1.1 to 0.003). There was no evidence
to suggest increased reductions in Hb among homo-/hemizygous children treated with CD
compared to placebo, SP or MQ.
Conclusions
While treatment with CD demonstrated greater reductions in Hb at 7 and 14 days after an
IPTi dose compared to both SP and MQ, there was no evidence that G6PD deficiency exac-
erbated the adverse effects of CD, despite evidence for higher hemolysis risk among
G6PDd infants.
Introduction
Substantial progress has been made in malaria control over the last decade, with many malaria
endemic countries now planning for malaria elimination [1]. The path to malaria elimination
is multi-faceted, requiring the detection of clinical cases and targeting of asymptomatic infec-
tions where parasite reservoirs are likely to persist and perpetuate onward transmission [2].
Antimalarial drugs play a central role in this endeavor; however, certain antimalarial drugs that
are key to many control and elimination strategies are unsafe among patients with glucose-
6-phosphate dehydrogenase (G6PD) deficiency and can cause hemolysis.
G6PD deficiency is the most common X-linked enzyme deficiency in humans, affecting
more than 400 million people worldwide [3]. Due to the X-linked nature of this deficiency,
females can be homozygous or heterozygous while males can only be hemizygous for the gene.
In consequence, partial inactivation of one female X chromosome or lyonization in somatic
cells, result in varying enzyme activity among heterozygous females depending on the propor-
tion of G6PD normal and G6PD deficient (G6PDd) red cells in their blood [4]. G6PD defi-
ciency is relatively common in historically malaria endemic countries. This overlap is not a
coincidence, as evidence suggests that G6PD deficiency arose through natural selection by
malaria: the parasite appears to undergo adaptive changes in G6PDd cells to confer protection
against malaria [5].
While variants of G6PD deficiency appear to provide partial protection against malaria [6–
8] it can also cause hemolysis after exposure to certain triggers, such as the ingestion of certain
foods (fava beans), infection (Hepatitis viruses A and B, cytomegalovirus, pneumonia, and
typhoid fever) and exposure to oxidant drugs [3, 9–13]. Drug-induced G6PD deficiency-related
hemolysis has been reported following therapy with a range of antimalarial drugs, including
primaquine, methylene blue, and the sulphone drug dapsone [14]. Additionally, dapsone is
used for a variety of indications [15], including in the treatment of leprosy, varied skin condi-
tions, and more recently Pneumocystis carinii [16], especially in patients with HIV infection,
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but can also be used in combination with antimalarial drugs (pyrimethamine, proguanil and
chlorproguanil) for malaria chemoprophylaxis and treatment [17].
In the late 1990s, chlorproguanil-dapsone (CD) was developed by a public-private partner-
ship as a low-cost treatment for uncomplicated Plasmodium falciparum (P. falciparum) malaria
in response to concerns of growing resistance to chloroquine and sulfadoxine-pyrimethamine
(SP) in Africa [16, 18]. CD was later withdrawn from the market in 2008 following demonstra-
tion of post-treatment hemolytic anemia in G6PDd patients in two phase III trials [19, 20].
Prior to this, in 2004, Gosling et al. undertook a study to examine the protective efficacy and
safety of three antimalarials–SP, mefloquine (MQ) and CD in an area of high SP resistance in
northeast Tanzania in search of alternative regimens to SP for Intermittent Preventive Treat-
ment for malaria in infants (IPTi) [21]. At the time, SP was used as first line treatment for
uncomplicated malaria nationally in Tanzania. Findings from this study—the Kilimanjaro
IPTi Drug Options Trial—showed that IPTi with the long acting drug MQ substantially
reduced the incidence of clinical episodes of malaria in children, but neither SP nor CD showed
signs of any protective efficacy against clinical malaria. High levels of SP resistance markers,
owing to evidence of increasing selection for individual dihydrofolate reductase (Pfdhfr) and
dihydropteroate synthetase (Pfdhps) mutations, offers an explanation for this lack of efficacy in
episodes of clinical malaria [22]. Regarding the safety of these three antimalarial drugs, more
deaths were observed in infants in the CD and MQ groups than in the SP or placebo groups.
The study also noted that children in the CD group experienced greater declines in mean
hemoglobin concentrations and had a higher risk of moderate anemia (hemoglobin<8 g/dL) 7
days after an IPTi dose. Children in the CD group also had a shorter time to first or only epi-
sode of moderate anemia than did those in the placebo or other drug groups [21]. Despite
these patterns, none of the analyses specifically documented the effect of G6PD status on
hemolysis and other adverse events, including hospitalization, blood transfusion, or death, in
children treated with these three IPTi antimalarial regimens. To our knowledge, this analysis is
the first to thoroughly examine the effects of G6PD deficiency in the context of IPTi in asymp-
tomatic children under the age of one year.
To address this gap, using existing data from the Kilimanjaro IPTi Drug Options Trial, we
explored differences in susceptibility to hemolysis and other adverse events among asymptom-
atic G6PDd infants treated with three antimalarial drugs in sub-Saharan Africa. Here, we
examine the joint effects of G6PD status and IPTi antimalarial treatment on incidence of
hemolysis. We hypothesized that incidence of hemolysis is increased among homo-/hemizy-
gous infants treated with CD compared to placebo and other antimalarials, especially within 7
days following treatment. First, we contrast absolute changes in hemoglobin levels up to 7, 14
and 28 days after an IPTi dose by treatment. Then we estimate the impact of G6PD status on
hemolysis among all infants who received active antimalarial treatment and assess for evidence
of modification of the effects of IPTi treatment on hemolysis by G6PD status. Finally, we assess
G6PD genotype effects on incidence of other adverse event episodes up to two years of age fol-
lowing IPTi.
Methods
Study design and study site
This is a secondary analysis of data from a clinical trial that took place between 2004 and 2008.
The drug trial has been described in detail elsewhere [21]. The protocol is also available as sup-
porting information (S1 Protocol). Briefly, the trial tested the protective efficacy and safety of
three antimalarial regimens for IPTi. The trial was a randomized, double-blind placebo-con-
trolled trial of SP, CD, and MQ, compared to placebo, conducted at neighboring moderate-
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and low-transmission sites in northeast Tanzania. Children aged 8–16 weeks who attended
clinics for WHO’s Extended Program on Immunization (EPI) were eligible for inclusion.
Enrolled children who met the inclusion criteria were randomly assigned to receive full treat-
ment doses of SP, CD, MQ, or placebo, given alongside routine immunizations at approxi-
mately 2, 3, and 9 months of age. Blood samples were collected before children were given their
first and third course of IPTi. Blood was also collected on filter paper bloodspots (Whatman
3MM) using the buffy coat. Hemoglobin measurements were made at IPTi doses, regular fol-
low-up and emergency visits. A total of 800 infants had their hemoglobin concentration sys-
tematically measured on day 7 after IPTi drug administration, including the first 200 infants to
receive the first course of IPTi and the second 200 infants to receive the third course at each
site. Every child was followed up at home on days 2 and 3 following treatment. During these
visits, health workers assessed for possible adverse events and checked for adherence to drug
regimens. In addition, all children were followed up at 10, 18, and 24 months of age. Additional
follow-up visits at 11 and 12 months of age were done on random samples (S1 Fig).
G6PD (A-) genotyping
G6PD screening was conducted using samples collected at routine visits at 9 months, focusing
on the G6PD deficiency allele 202A G6PD A-, the most common in sub-Saharan Africa.
Whole blood samples were collected and centrifuged on the day of collection. Plasma, buffy
coat and red cells were stored at -20°C locally and transferred to the central laboratory for
G6PD testing at a later date. Filter paper bloodspots (Whatman 3MM) for each patient were
prepared using the collected buffy coat. DNA extraction from the impregnated filter papers
was done using the Chelex method as previously described [23]. The extracted DNA samples
were genotyped using a simple high-throughput sequence-specific oligonucleotide probe
(SSOP)-ELISA method described by Enevold et al. [24] to detect the most prominent single
nucleotide polymorphisms (SNPs) in the G6PD genes (B, A and A-).
Ethics
The clinical protocol of the original study was approved by the National Medical Research
Coordination Committee of the National Institute for Medical Research of Tanzania
(NIMR-MRCC) and by the London School of Hygiene and Tropical Medicine ethics commit-
tee and registered with ClinicalTrials.gov (identifier: NCT00158574).
Study population
For this analysis, only children whose G6PD status could successfully be determined were
included.
Variables and definitions
Homozygous females and hemizygous males were considered G6PDd and analyzed together,
because of small numbers. Heterozygous G6PD females were analyzed as a separate category.
The primary safety endpoint considered for this analysis was incidence of hemolysis. We
used hemoglobin as a surrogate for hemolysis using two measures. First, hemolysis was defined
as the absolute change in hemoglobin, from the day of the most recent IPTi dose. We also
defined hemolysis as any post-dose hemoglobin measurement<8 g/dL (a measure of moderate
anemia).
For each outcome definition, we evaluated hemolysis using two approaches. The first
restricted the analysis to children who had their hemoglobin concentration systematically
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measured on day 7 after an IPTi dose. The second considered any follow-up hemoglobin mea-
surements obtained from 1 to 14 or 28 days after each IPTi dose administration, provided it
was obtained before the next IPTi dose. The time frames for follow-up hemoglobin measure-
ments were chosen to reflect what is known about the duration of drug-induced hemolytic epi-
sodes. Typically, within 24–72 hours of drug dosing, clinically detectable hemolysis and
jaundice become apparent, worsening until days 7–8 [3]. Studies have shown that hemoglobin
concentrations after use of oxidant drugs are typically lowest on day 7 [19, 25, 26]. Once such
drugs are discontinued, hemoglobin concentrations begin to recover after 8–10 days [3].
We also assessed treatment and genotype effects on incidence of adverse events (malaria,
hospitalizations, blood transfusions, and death) throughout the study period.
Directed acyclic graphs were used to identify potential confounders of G6PD status. In con-
trast to many conventional epidemiologic risk factors, genotype is not affected by most risk fac-
tors for hemolysis or malaria. However, G6PD deficiency does vary by sex, a potential risk
factor for study outcomes. Moreover, genotype varies by distance above sea level (and accord-
ingly site), a risk factor for malaria if not hemolysis, probably due to the selective pressure of
malaria endemicity on the source population. Accordingly, genotype effect estimates were
adjusted for these potential confounders.
Statistical analysis
All analyses were performed using STATA 13.1 (STATA Corporation, College Station, TX,
USA).
Linear and logistic models were used for continuous and binary hemolysis outcomes mea-
sured only once for each infant. For repeated continuous and binary outcomes, mixed effects
linear and logistic models with random intercepts were used. Analyses exploring G6PD geno-
type effects on hemolysis were restricted to children in the active arms, motivated by the
hypothesis that adverse effects of G6PD deficiency would only be observed in infants receiving
active treatment. Analyses were adjusted for sex and elevation, either directly or using inverse
weighting by way of propensity scores for rare binary and failure time outcomes. Propensity
scores, an alternative approach to standard adjustment for covariates, are useful when a binary
or categorical exposure is common, but the binary or failure time outcome is rare, and when
there are a large number of potential confounders that must be accounted for [27]. In analyses
of changes in hemoglobin, we also adjusted for treatment assignment, dose number, weight
and elevation. For each hemolysis outcome, we assessed genotype-treatment interactions.
Poisson models were used to estimate genotype effects on incidence of hemolysis and sec-
ondary adverse event outcomes, adjusting for treatment, gender, site, and elevation, with fol-
low-up censored at 24 months of age or on the date of exit for children lost to follow-up due to
migration, refusal, or exclusion. As in the main trial analysis, children were considered not at
risk for malaria for 21 days after receipt of treatment with an antimalarial drug, not at risk for
hemolysis for 28 days after a hemolytic episode [28], and not at risk for hospitalization for 7
days after hospital admission.
Results
Baseline characteristics
A total of 2419 children were enrolled in the original trial, of whom 1842 (76%) were screened
for G6PD deficiency. Among those screened, 1557/1842 (85%) were successfully genotyped
and included in this analysis. G6PD results were not obtained for the remaining 285
patients (15%) either because samples were not received or DNA extraction was not successful.
Among the genotyped children, 1129 (73%) returned for at least one follow-up hemoglobin
Hemolytic Risk in G6PD Deficient Infants Given IPTi Malaria Regimens
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measurement within 28 days of an IPTi dose. In addition, a randomly selected 447 (28%)
returned for a day 7 follow-up hemoglobin measurement (Fig 1).
Demographic and clinical characteristics at enrollment among children with valid genotyp-
ing results were generally similar across genotypes, with a few exceptions (Table 1). Sex differ-
ences (p<0.001) are explained by the fact that the heterozygous genotype only exists in
females. Children from the high transmission site (Korogwe) (p = 0.003) and those who lived
at lower median elevations from sea level (p = 0.002) were more likely to be homo-/hemizy-
gous. Homo-/hemizygous children also displayed lower median hemoglobin levels (p = 0.004)
and slightly higher median weight values at enrollment (p = 0.005). Compared to children with
successful G6PD genotyping results, included in this analysis, excluded children (those with no
Fig 1. Trial profile for the entire cohort (both sites combined). SP = sulfadoxine-pyrimethamine. CD = chlorproguanil-dapsone. MQ =mefloquine.
HET = heterozygous. HH = homo-/hemizygous.
doi:10.1371/journal.pone.0142414.g001
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or invalid G6PD genotype, n = 855) were more likely to be male (p = 0.004), lived closer to the
nearest clinic (p = 0.002), and displayed higher bednet coverage (p = 0.02) (S1 Table).
Treatment effects on changes in hemoglobin up to 28 days after an IPTi
dose
In analyses adjusting for genotype, sex, dose number, site, and elevation, treatment with CD
reduced hemoglobin levels by approximately 0.5 g/dL 7 days after an IPTi dose, by a similar
amount within 14 days, and by 0.2 g/dL within 28 days, compared to placebo (Table 2).
Adjusted declines in the CD group were also generally larger than in the MQ and SP groups,
which did not differ from placebo.
Genotype effects on hemolysis up to 28 days after an IPTi dose among
children given active treatment
In analyses examining the impact of G6PD status on hemolysis among 329 children in the
active treatment arms, adjusting for sex and elevation using inverse weighting, we found a
strong association of homo-/hemizygous genotype with hemoglobin<8 g/dL 7 days after IPTi
treatment (adjusted odds ratio = 6.7, 95% CI 1.7 to 27.0, p = 0.01) (Table 3). This was an
uncommon outcome, with only 6 events (2%) in the normal group (n = 281), 4 events (17%) in
the homo-/hemizygous group (n = 24), and no events in the heterozygous group (n = 29)
(p = 0.01). On day 7, there was also borderline evidence of a greater average decline in hemo-
globin among homo-/hemizygous children compared to normal children (-0.6 g/dL, 95% CI
Table 1. Demographic and clinical data at enrollment among G6PD genotyped children with successful G6PD genotyping results.
Characteristic Normal (n = 1324) Heterozygous (n = 119) Homo-/hemizygous (n = 114) P-value
Age (weeks) 9.0[8.0–10.0] 9.0[8.0–10.0] 9.0[9.0–10.0] 0.3
Weight (kg)δ 5.5[5.1–6.0] 5.5[5.0–5.9] 5.7[5.2–6.2] 0.005 Λ
Hemoglobin (g/dL)λ 10.7[9.9–11.5] 10.7[10.0–11.4] 10.2[9.3–11.3] 0.004Λ
Elevation from sea level (m)§ 359[315–580] 355[311–565] 329[310–541] 0.002
Distance to nearest clinic (km)Φ 2.2[1.1–4.6] 2.2[1.0–4.9] 1.7[0.9–4.2] 0.2
Witnessed bednet coverage 1169(88.3) 104(87.4) 101(88.6) 1.0
Reported ITN coverage 724(54.7) 69(58.0) 67(58.8) 0.6
Rural residence¶ 819(62.0) 78(65.6) 70(61.4) 0.7
Girls 630(47.6) 119(100.0) 40(35.1) [-]τ
Korogwe 700(52.9) 65(54.6) 79(69.3) 0.003
Treatment
Placebo 333(25.2) 33(27.7) 29(25.4) 0.8
SP 330(24.9) 34(28.6) 25(21.9)
CD 333(25.2) 25(21.0) 28(24.6)
MQ 328(24.8) 27(22.7) 32(28.1)
Data are median [IQR] or n (%). SP = sulfadoxine-pyrimethamine. CD = chlorproguanil-dapsone. MQ = meﬂoquine.
δData missing for 3 patients in the normal group.
λData missing for 17 patients in the normal group, 1 patient in the homo-/hemizygous group, and 1 patient in the heterozygous group.
§Data missing for 2 observations in the normal group.
ΦData missing for 2 patients in the normal group.
¶Data missing for 2 patients in the normal group.
ΛA parametric test was used after assessment of normality.
τ The probability of a heterozygote being female is 1; the event is certain to occur and cannot be explained by chance.
doi:10.1371/journal.pone.0142414.t001
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-1.1 to 0.003, p = 0.05). In contrast, we found little or no evidence for a genotype effect on
either outcome within 14 or 28 days of an IPTi dose.
Effect modification by G6PD status on incidence of hemolysis up to 28
days after an IPTi dose
In analyses stratified by genotype and adjusting for dose number, sex, site, weight and elevation,
treatment with CD reduced hemoglobin by nominally larger amounts in the homo-/hemizygous
group (range: 0.49–1.31 g/dL) than among normal genotype children (range: 0.18–0.48 g/dL)
(Table 4), but there was no persuasive evidence for treatment-genotype interaction in any of
these analyses (p>0.05, test for interaction of CD vs. placebo and homo-/hemizygous
Table 2. Adjusted treatment effects on changes in hemoglobin 7, 14, and 28 days after an IPTi dose.
Adjusted between-group differences (g/dL) [95%CI]
7 days after an IPTi dose 14 days after an IPTi dose 28 days after an IPTi dose
Treatment Estimate P-valuea Overall
p-valueb
Estimate P-value a Overall
p-valueb
Estimate P-valuea Overall p-
valueb
Placebo Ref 0.01 Ref <0.001 Ref 0.07
SP 0.00 [-0.34 to
0.34]
1.0 0.06 [-0.22 to
0.34]
0.7 -0.07 [-0.28 to
0.13]
0.5
MQ 0.10 [-0.26 to
0.45]
0.6 -0.03 [-0.31 to
0.26]
0.8 0.08 [-0.13 to
0.29]
0.5
CD -0.45 [-0.80 to
-0.09]
0.01 -0.50 [-0.79 to
-0.22]
0.001 -0.19 [-0.40 to
0.01]
0.07
Analyses adjusted for genotype, dose number, sex, site, weight (kg) and elevation (m).
aP-values for adjusted treatment effects compared to chlorproguanil-dapsone (CD).
bP-values for overall adjusted treatment effects. SP = sulfadoxine-pyrimethamine. MQ = meﬂoquine.
doi:10.1371/journal.pone.0142414.t002
Table 3. Adjusted genotype effects on hemolysis 7, 14, and 28 days after an IPTi dose among treated infants.
Adjusted between-group differences (g/dL) [95% CI]
7 days after an IPTi dose 14 days after an IPTi dose 28 days after an IPTi dose
Hemolysis endpoint N Estimate P-value N[Nobs] Estimate P-value N[Nobs] Estimate P-value
Absolute declinesa
Normal 281 Ref 409[450] Ref 706[913] Ref
Heterozygous 29 -0.08 [-0.6 to 0.5] 0.8 39[43] -0.09 [-0.6 to 0.4] 0.7 70[87] -0.2 [-0.5 to 0.2] 0.3
Homo-/hemizygous 24 -0.6 [-1.1 to 0.003] 0.05 34[39] -0.4 [-0.8 to 0.1] 0.1 62[79] -0.3 [-0.6 to 0.1] 0.1
Adjusted odds ratio [95% CI]
7 days after an IPTi dose 14 days after an IPTi dose 28 days after an IPTi dose
N Estimate P-value N[Nobs] Estimate P-value N[Nobs] Estimate P-value
Declines to less than 8 g/dLb
Normal 281 Ref 451[530] Ref 769[1136] Ref
Heterozygousc 29 - - 40[49] 0.9 [0.2 to 3.7] 0.8 74[101] 0.6 [0.2 to 2.1] 0.5
Homo-/hemizygous 24 6.7 [1.7 to 27.0] 0.01 35[41] 2.9 [1.03 to 8.4] 0.04 66[93] 1.3 [0.5 to 3.2] 0.6
Analyses were restricted to children in the active arms on the assumption that adverse effects of G6PD deﬁciency are only observed in infants receiving
active treatment.
aAdjusted for intervention arm, dose number, sex, site, weight (kg) and elevation (m).
bAdjusted for sex and elevation (m) using inverse probability to treatment weights.
cAll observations were dropped due to no events. N[Nobs] = number of unique infants[number of observations].
doi:10.1371/journal.pone.0142414.t003
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vs. normal). Due to few events, we were unable to explore effect modification by G6PD status on
hemogobin<8 g/dL at day 7 or within 14 or 28 days of an IPTi dose.
Genotype effects on adverse event episodes up to 2 years of age
During a median follow-up time of 21.8 months, 314 children experienced at least one episode
of clinical malaria, for a total of 707 episodes, including 598 in the normal genotype group, 67
among heterozygous children, and 42 among the homo-/hemizygous group. There were also a
total of 954 hospitalizations: 362 participants had one hospitalization, 155 had two, and 85
Table 4. Adjusted treatment effects on changes in hemoglobin 7, 14, and 28 days after an IPTi dose, by G6PD genotype.
Adjusted between-group differences (g/dL) [95%CI]
7 days after an IPTi dose 14 days after an IPTi dose 28 days after an IPTi dose
Genotype Treatment Estimate P-
valuea
P-value, test
for
interactionb
Estimate P-
valuea
P-value, test
for
interactionb
Estimate P-
valuea
P-value, test
for
interactionb
Normal
Placebo Ref 0.9(0.8) Ref 0.5(0.2) Ref 0.7(0.4)
SP -0.03
[-0.40 to
0.35]
0.9 0.09 [-0.22
to 0.40]
0.6 -0.03
[-0.25 to
0.20]
0.8
MQ 0.02 [-0.37
to 0.41]
0.9 -0.08
[-0.39 to
0.23]
0.6 0.07 [-0.16
to 0.30]
0.5
CD -0.44
[-0.82 to
-0.06]
0.02 -0.48
[-0.79 to
-0.18]
0.002 -0.18
[-0.40 to
0.05]
0.1
Heterozygous
Placebo Ref Ref Ref
SP 0.38 [-0.68
to 1.44]
0.5 0.39 [-0.49
to 1.27]
0.4 -0.05
[-0.70 to
0.60]
0.9
MQ 0.48 [-0.74
to 1.70]
0.4 0.70 [-0.34
to 1.74]
0.2 0.07 [-0.66
to 0.79]
0.9
CD -0.40
[-1.68 to
0.88]
0.5 -0.19
[-1.20 to
0.83]
0.7 -0.12
[-0.85 to
0.60]
0.7
Homo-/
hemizygous
Placebo Ref Ref Ref
SP -0.40
[-2.07 to
1.27]
0.6 -0.89
[-2.07 to
0.29]
0.1 -0.69
[-1.51 to
0.13]
0.1
MQ 0.41 [-1.06
to 1.87]
0.6 -0.34
[-1.51 to
0.83]
0.6 0.15 [-0.65
to 0.95]
0.7
CD -0.65
[-2.10 to
0.80]
0.4 -1.31
[-2.43 to
-0.19]
0.02 -0.49
[-1.25 to
0.28]
0.2
Analyses adjusted for dose number, sex, site, weight (kg) and elevation (m).
aP-values for adjusted treatment effects by G6PD genotype compared to chlorproguanil-dapsone (CD).
bP-values for overall interaction in stratiﬁed analyses (p-values for interaction of CD vs. placebo and homo-hemi vs. normal). MQ = meﬂoquine.
SP = sulfadoxine-pyrimethamine.
doi:10.1371/journal.pone.0142414.t004
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were hospitalized three or more times. There was no evidence for differences in malaria inci-
dence or hospitalizations by G6PD genotype. Thirty-four children received blood transfusions,
including three who required more than one transfusion, for a total of 38 events. Seven children
died, including two in the homo-/hemizygous group (one in the CD arm); the remaining
deaths were among G6PD normal children. These outcomes were too uncommon for mean-
ingful statistical analysis (S2 Table).
Discussion
Our analysis of the effects of antimalarial regimens and G6PD status on hematologic parame-
ters in asymptomatic children treated with IPTi showed that treatment with CD caused reduc-
tions in hemoglobin at 7 and 14 days after an IPTi dose, relative to placebo, SP, and MQ. We
also found evidence for higher hemolysis risk among G6PDd infants. Although we found no
clear evidence that G6PD deficiency exacerbated the adverse effects of CD, the study was not
powered to detect an interaction between these two factors.
The transient but statistically significant decrease in hemoglobin after initiation of antimalar-
ial treatment is consistent with previous studies examining the hematologic variations in pediat-
ric uncomplicated P. falciparummalaria and corresponding trends during post-treatment
follow-up [29]. Furthermore, the hemolytic potential of CD in this context has been widely docu-
mented and clinically important decreases in hemoglobin or related adverse events requiring
medical intervention post-treatment have been noted [19, 20, 30, 31]. Our analysis also revealed
a strong association of homo-/hemizygous G6PD genotype with post-dose incidence of anemia
(hemoglobin<8 g/dL) 7 days after IPTi treatment. Homo-/hemizygous infants also displayed
borderline significant evidence of greater absolute declines in hemoglobin compared with normal
infants at day 7. This is consistent with expectations and the clinical-hematological picture of
drug-induced acute hemolytic anemia in G6PDd patients [16, 32, 33].
Drug induced hemolysis is self-limiting in individuals with G6PD deficiency [34]. In this
study we show that hemoglobin levels are temporarily reduced, with hemoglobin declines
appearing less pronounced within 28 days. Research has shown that the mechanism for this is
explained through the destruction of older red blood cells during drug exposure that are the
most enzyme deficient while young erythrocytes with nearly normal levels of G6PD are resis-
tant to destruction [34, 35].
Some limitations to our analysis should be noted. As previously described, many analyses
were underpowered, in particular for treatment-genotype interactions, due to the low fre-
quency of homo-/hemizygous and heterozygous genotypes. Assessing the hematological effects
of antimalarials is complicated, especially when the risk of adverse reactions is confined to a
relatively small subgroup of patients—those with G6PD deficiency—and demonstrating a sta-
tistically significant trend is unlikely. Further, we conducted multiple comparisons, potentially
inflating the overall type-I error rate. Additionally, analyses were restricted to children who
survived and remained in follow-up to 9 months of age, and had valid G6PD results, with the
potential to induce selection bias and limit the generalizability of our findings. However, base-
line characteristics of the children with valid G6PD results were generally similar to those who
were excluded from the analysis. An additional limitation is that G6PD deficiency was deter-
mined by screening human DNA for a single SNP in the G6PD gene (G202A), although muta-
tions other than G6PD A- could have affected hemolysis risk and explain part of the observed
results. However, this is unlikely to be important, because G6PD A- accounts for 90% of G6PD
deficiency in Africa [3].
These limitations render it challenging to find true subgroup effects, partially explaining
why there is currently limited data concerning the hemolytic risk associated with diverse
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antimalarial drug regimens across G6PD genotypes in most populations. This analysis was
underpowered to detect interaction; nonetheless, the direction of trends is consistent with
expectations that IPTi with CD may produce greater reductions in hemoglobin among homo-/
hemizygous children compared to other antimalarials. CD was withdrawn from the market in
2008 due to post-licensure hemolytic toxicity in patients with G6PD deficiency; however, dap-
sone is still used in the prevention and treatment of a variety of diseases [15–17, 36] and can
precipitate life-threatening hemolysis in individuals with G6PD deficiency. In addition, two
8-aminoquinoline drugs with similar safety profiles, primaquine and tafenoquine, are attract-
ing much interest as chemotherapeutic and prophylactic antimalarial agents against the liver
stages of P. vivax and P. falciparum. Both drugs also cause oxidant hemolysis in individuals
with G6PD deficiency, and as malaria control programs begin to consider the use of prima-
quine or tafenoquine (if approved and licensed), identifying subgroups for which antimalarial
treatment may be harmful or likely to have the largest benefit will become increasingly impor-
tant. While this may prove challenging given the rarity of G6PD deficiency, even if fixed by
design, pooled analyses with larger samples of G6PDd individuals could offer new insights.
Interaction analyses can enable us to substantiate clinically important differences in hemato-
logical effects for oxidative antimalarial treatments across G6PD genotypes, and approaches to
examine such trends in this important patient population are needed.
Conclusion
This re-analysis of data from the Kilimanjaro IPTi Drug Options Trial among nearly 1600 chil-
dren from northeastern Tanzania showed that treatment with CD as well as G6PD deficiency
were associated with declines in hemoglobin and increased risk of moderate anemia. However,
despite a fairly large sample, the study was underpowered to determine whether the adverse
effects of CD are exacerbated among infants with G6PD deficiency, primarily because these defi-
cient G6PD genotypes were uncommon. Combining data from a series of similar, well-conducted
primary studies could offer a way to answer this question and optimize the targeting of treatment,
which is increasing in importance as systematic treatment with drugs with hemolytic potential,
such as the 8-aminoquinolines, primaquine and tafenoquine, becomes more widespread.
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